[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cell-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cell-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,76,122,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100631785","phase-1-safety-and-efficacy-of-fap-icdc-in-ischemic-cardiomyopathy-100631785",false,"NCT07505199","Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy","Safety and Efficacy of FAP-Targeted Immunosuppressive CAR-DC in the Treatment of Ischemic Cardiomyopathy","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years.\n* Diagnosis of ischemic cardiomyopathy, with at least 3 months of optimized guideline-directed medical therapy (GDMT) at maximally tolerated doses; left ventricular ejection fraction (LVEF) \\\u003C35%; New York Heart Association (NYHA) functional class III-IV.\n* Ability to understand the risks, benefits, and treatment alternatives of immunoregulatory CAR-DC therapy, and willingness to participate in the study; the patient or his\u002Fher legally authorized representative must provide written informed consent prior to study enrollment.\n* Adequate hematologic function defined as: hematocrit \\>30%, lymphocyte count \\>0.5 × 10⁹\u002FL, and platelet count \\>60 × 10⁹\u002FL.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year due to non-cardiac conditions.\n\nCardiac resynchronization therapy (CRT) implantation within 3 months prior to enrollment or planned CRT implantation.\n\nPercutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 3 months prior to enrollment OR plan to PCI.\n\nPresence of non-ischemic cardiomyopathy, including but not limited to dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic cardiomyopathy, peripartum cardiomyopathy, inflammatory or immune-mediated cardiomyopathy, metabolic or genetic cardiomyopathy, or cardiomyopathy secondary to moderate-to-severe valvular heart disease, congenital heart disease, or other non-ischemic etiologies.\n\nPersistent hemodynamic instability.\n\nEnd-stage renal disease (eGFR \\\u003C25 mL\u002Fmin\u002F1.73 m²) requiring or receiving renal replacement therapy (hemodialysis or peritoneal dialysis).\n\nActive autoimmune disease requiring immunosuppressive therapy.\n\nHistory of malignancy.\n\nActive infection, including but not limited to active hepatitis B (HBV DNA \\>1000 copies\u002FmL by PCR), hepatitis C, syphilis, or human immunodeficiency virus (HIV) infection, or uncontrolled systemic fungal, bacterial, viral, or other infections.\n\nPregnant women.\n\nKnown contraindications to the investigational product or study-related procedures.","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (iCDC) therapy in patients with ischemic cardiomyopathy, and to explore its potential as a novel therapeutic strategy for this disease.",[27,28],"Ischemic Cardiomyopathy","Cell Therapy",[30,31,32],"ischemic cardiomyopathy","dendritic cell","immune tolerance","RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":37},"2026-05-21",{"date":41,"type":21},"2029-04-01",{"name":43,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100580644","phase-1-cd19-directed-chimeric-antigen-receptor-autologous-t-cells-cart19-for-lupus-100580644","NCT06839976","CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus","CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Adolescents and Young Adults With Systemic Lupus Erythematosus (SLE)","Inclusion Criteria:\n\n1. Signed informed consent form must be obtained prior to any study procedure. Labs or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required window.\n2. Patient age must be 12-29 years, inclusive, at time of enrollment.\n3. Meeting ACR\u002FEULAR Classification Criteria for SLE\n4. ANA positive \\> 1:80 and\u002For double-stranded DNA (dsDNA) positive\n5. Active (refractory) disease, defined as follows:\n\n   a. Lupus nephritis subjects must meet both the following criteria: i. ISN\u002FRPS active nephritis Class III\u002FIV +\u002F- V lupus nephritis diagnosed by biopsy within past 12 months.\n\nii. Persistent and clinically significant: ≥2 measurements with urine protein with either of the following:\n\n1. \\> 1mg\u002Fmg creatinine\n2. \\> 0.5 mg\u002Fmg creatinine associated with renal dysfunction or low albumin.\n3. \\> 0.5 mg\u002Fmg creatinine in a patient with rising proteinuria after prior complete renal response b. Non-renal SLE subjects must meet either of the following criteria: i. SLEDAI-2K ≥ 8 and clinical SLEDAI-2K ≥ 6 ii. Inability to decrease prednisone ≤7.5mg\u002Fday or 0.15mg\u002Fkg\u002Fday, whichever is lower, due to active disease.\n\n6\\. Patients must have had at least 3 months of cumulative conventional therapy defined as:\n\n1. Conventional induction immunosuppressive agent(s) (e.g., mycophenolate mofetil, cyclophosphamide), and\n2. At least one additional therapy:\n\ni. B-cell directed biologic therapy (e.g., rituximab, belimumab, ofatumumab, obinutuzumab) ii. Calcineurin inhibitor (e.g., tacrolimus, cyclosporine, voclosporin) iii. Other immunosuppressive medication for SLE (e.g., anifrolumab, abatacept, JAK inhibitor) 7. Adequate organ function status\n\n1. Renal: eGFR must be ≥30 and subject cannot be receiving dialysis.\n2. Hepatic: Transaminases \\\u003C 5x upper limit of normal and serum conjugated (Direct) bilirubin \\\u003C1.5x upper limit of normal unless attributable to SLE. If attributable to autoimmune disease, Child-Pugh score must be class A or class B. Child-Pugh score cannot be class C.\n3. Cardiac: Shortening fraction \\> 28%, left ventricular ejection fraction \\>45%, and no evidence of severe pulmonary hypertension\n4. Pulmonary: Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and \\\u003CGrade 3 hypoxia; DLCO ≥40% (corrected for anemia and\u002For VA volume if necessary) if PFTs are clinically appropriate as determined by the treating investigator.\n\n   8\\. Subjects of reproductive potential must agree to use acceptable birth control methods.\n\nExclusion Criteria:\n\n1. Active, untreated infections\n2. HIV infection\n3. Active Hepatitis B\n\n   a. Patients must have a negative hepatitis B surface antigen to be enrolled on this study.\n4. Active Hepatitis C\n5. Patients with severe neuropsychiatric lupus or neurologic manifestations of SLE (e.g. stroke, seizure, psychosis, demyelinating syndromes, organic brain syndrome, or lupus related headaches)\n6. Monogenic lupus (known)\n7. Previous autologous or allogenic stem cell transplant\n8. Previous kidney transplant\n9. History of seizure disorder\n10. Patients who are on anti-epileptic therapy\n11. Participation in a clinical trial in which the patient receives an investigational drug within a time period equal or less than 5.5 half-lives of the investigational agent prior to study enrollment.\n12. Subjects who are unwilling or unable to discontinue immunosuppressive medications at the times of CART19 infusion will be excluded from the trial\n13. Any comorbidity that in the opinion of the investigators would jeopardize the ability of the subject to tolerate therapy.\n14. Pregnant patients. All participants of childbearing potential must have negative pregnancy test.\n15. Lactating participants who want to continue breastfeeding.\n16. Patients who are unwilling to consent to LTFU","12 Years","29 Years",{"count":56,"type":21},24,[24,58],"PHASE2","This is a single-center, single-arm, open-label phase 1\u002F2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE).\n\nPhase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE). There is no planned dose escalation, but a dose de-escalation will be made based on the incidence of Dose Limiting Toxicities. Phase 2 will evaluate the efficacy and further evaluate the safety of CART19 in this population.",[61,62,63,64,28,65,66],"SLE","Systemic Lupus Erythematosus (SLE)","CAR T Cell","CART19","Lupus","Lupus Nephritis (LN)","2026-06-11",{"date":69,"type":37},"2026-06-15",{"date":71,"type":37},"2025-05-06",{"date":73,"type":21},"2030-02-28",{"name":75,"class":44},"Children's Hospital of Philadelphia",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":45},"100565518","early-phase-1-exercise-as-an-immune-adjuvant-for-allogeneic-cell-therapies-100565518","NCT06643221","Exercise as an Immune Adjuvant for Allogeneic Cell Therapies","Exercise-induced Adrenergic Receptor Signaling as an Immune Adjuvant for Allogeneic Cell Therapies","Allo-X","Procedures are in place for protecting against or minimizing the risks to the healthy volunteers recruited for this study. Physical risk to volunteers and matched related donors will be protected through health screening to determine study eligibility, and medical monitoring with an established test termination criterion during the exercise and isoproterenol infusion trials.\n\nTo protect against the remote risk of an adverse cardiac event occurring during exercise and isoproterenol infusion, the study will only enroll volunteers who are considered \"low risk\" for maximal stress testing in accordance with the guidelines published by the American College of Sports Medicine (ACSM) and American Heart Association (AHA). Individuals who are considered \"low risk\" are men and women who are asymptomatic and have no more than one risk factor for cardiovascular disease (CVD). The risks to subjects are therefore extremely low. All infusions will take place in the Clinical and Translational Sciences Research Center (CATS) Infusion Suite, which is a designated University of Arizona campus facility for infusion trials and equipped with appropriate medical personnel and monitoring equipment (i.e. ECG). The graded exercise tests and isoproterenol infusions procedures will be performed under the direction of a licensed and board-certified cardiologist\n\nInclusion Criteria:\n\nParticipants must:\n\n* Be between 21 and 55 years of age.\n* Be classified as 'low-risk' for graded exercise\u002Fstress testing according to ACSM-AHA criteria.\n* Have no contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast as per FDA guidelines.\n\nExclusion Criteria:\n\nParticipants will be excluded if they:\n\n* Currently use tobacco products or have quit within the last 6 months.\n* Have a body mass index (BMI) greater than 34 kg\u002Fm² or waist circumference exceeding 102 cm for men and 88 cm for women.\n* Use any medications known to affect the immune system or regularly take ibuprofen\u002Faspirin, antidepressants, or medications that alter blood pressure or cardiovascular function.\n* Use of hormone replacement therapy.\n* Are pregnant or breastfeeding.\n* Have chronic or debilitating arthritis or have been bedridden in the past three months.\n* Experienced a common illness (e.g., colds) within the past 6 weeks.\n* Have central or peripheral nervous disorders, a history of stroke, or major affective disorder.\n* Are infected with HIV or hepatitis or have any autoimmune disease.\n* Have known cardiovascular disease or contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast.\n* Use any prescription medications or have an allergy to beta-blockers.\n* Have a resting heart rate of less than 50 beats per minute.\n* Suffer from asthma, emphysema, bronchitis, kidney disease, pheochromocytoma, diabetes, overactive thyroid, or a history of severe anaphylactic reactions.\n* Are scheduled for surgery.\n\nAdditionally, participants who meet the inclusion criteria but present with more than one of the following cardiovascular disease (CVD) risk factors will be excluded unless cleared by a cardiologist:\n\n* Family History: Myocardial infarction, coronary revascularization, or sudden death before 55 years of age in a father or male first-degree relative, or before 65 years of age in a mother or female first-degree relative.\n* Hypertension: Systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg.\n* Dyslipidemia: Total serum cholesterol exceeding 200 mg\u002Fdl.\n* Pre-diabetes: Fasting blood glucose levels between 100 mg\u002Fdl and 126 mg\u002Fdl.",true,"21 Years","55 Years",{"count":88,"type":21},200,[90],"EARLY_PHASE1","This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a cancer patient, usually to help prevent or treat cancer relapse after a stem cell transplant. These donor cells can either be directly infused into the patient or grown in a lab to create more specialized immune cells that target and kill cancer. While this therapy has been helpful for many patients, there is a need to make it more effective for a larger group and reduce side effects like graft-versus-host disease (GvHD), where the donor's immune cells attack the patient's healthy tissue.\n\nThis Early Phase 1 trial will test whether exercise can help produce better immune cells from donors. The investigators will recruit healthy participants for three study groups:\n\n1. Exercise Group: Participants will complete a 20-minute cycling exercise session. The investigators will collect blood samples before, during, and after exercise to study the number and quality of immune cells. The investigators will also use the collected cells to create immune therapies and test their ability to kill cancer cells in the lab and control cancer growth in mice.\n2. Exercise and Beta Blocker Group: In this group, participants will complete up to five cycling sessions, with at least a week between each session. Before each session, participants will take either a placebo or a drug (beta blocker) that blocks stress hormones like adrenaline. The investigators will collect blood samples before and during exercise to see how blocking these hormones changes the effect of exercise on immune cells.\n3. Isoproterenol Group: Participants in this group will receive a 20-minute infusion of isoproterenol, a drug that mimics the effects of adrenaline. The investigators will collect blood samples before, during, and after the infusion to see if the drug causes similar immune changes to those caused by exercise.\n\nParticipants can join one, two, or all three groups. This research will help understand whether exercise can improve immune cell therapies for treating blood cancer and reduce the risk of GvHD, making these treatments safer and more effective.",[93,94,95,96,97,28],"Leukemia","Hematopoetic Stem Cell Transplantation","Donor Lymphocyte Infusion","CAR T-Cell Therapy","Lymphoma",[99,100,101,102,103,104,105,106,107,108,109,110,111,112],"exercise","cell therapy","beta-blockers","immune function","phosphodiesterase inhibitor","CAR T-cells","NK-cells","cytokine-induced killer cells","cytokine-induced memory-like NK-cells","monoclonal antibodies","leukemia","lymphoma","donor lymphocyte infusion","gamma-delta T-cells","2026-06-03",{"date":115,"type":37},"2026-06-05",{"date":117,"type":37},"2018-01-24",{"date":119,"type":21},"2031-05-31",{"name":121,"class":44},"University of Arizona",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":45},"100560302","phase-2-single-arm-pilot-trial-of-letermovir-for-cmv-prophy-in-car-t-cell-100560302","NCT06575374","Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell","Open Label Single Arm Pilot Trial of Letermovir for Cytomegalovirus Prophylaxis After Axicabtagene Ciloleucel Therapy","Inclusion Criteria:\n\n1. Age ≥ 18 years of age.\n2. Have an ECOG performance status of 0 or 1.\n3. The participant must be scheduled for SOC AXI-CEL.\n4. The participant must be seropositive for CMV (defined as having anti-CMV IgG antibodies)\n5. Creatinine clearance \\> 10 mL\u002Fmin\n6. Child Pugh class A or B if liver disease is present.\n7. Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately.\n8. Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection not responding to treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n2. Female participants who are pregnant or breastfeeding.\n3. Unwilling or unable to follow protocol requirements.\n4. Planned to receive any other anti-CMV therapy such as high dose acyclovir (500 mg\u002Fm2\u002Fdose intravenously every 8 hours or 800 mg orally 4 times a day) or high dose valacyclovir (2 grams three to four times daily or 2 grams three times daily) for the prophylaxis of CMV reactivation. Acyclovir or valacyclovir at lower doses for the prevention of HSV and VZV are allowed.\n5. Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug.\n6. Evidence for CMV infection defined as any positive CMV DNA qPCR test within 1 week prior to starting letermovir.\n7. Child Pugh class C liver disease.",{"count":130,"type":21},36,[58],"The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.",[28],"2026-01-20",{"date":136,"type":37},"2026-01-21",{"date":138,"type":37},"2024-12-12",{"date":140,"type":21},"2027-08-01",{"name":142,"class":44},"M.D. Anderson Cancer Center",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":151,"minAge":17,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":162,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":45},"100607040","phase-1-msc-exosome-therapy-for-post-preeclampsia-endothelial-dysfunction-100607040","NCT07183384","MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction","The Effectiveness of Mesenchymal Stem Cell-Derived Exosome Therapy in Improving Endothelial Dysfunction in Postpartum Mothers With a History of Preeclampsia","EXITPE","Inclusion Criteria:\n\n* Postpartum\n* Confirmed diagnosis of preeclampsia in the last pregnancy\n* Postpartum period of first week and second week\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of chronic hypertension prior to pregnancy\n* Major cardiovascular disease history\n* Active systemic infection\n* Endothelial Injury history\n* Active smoking status including vape, alcohol, drug addiction.","FEMALE","50 Years",{"count":154,"type":21},80,[24,58],"\\---\n\nWhy Is This Study Being Done?\n\nWomen who have preeclampsia during pregnancy face a much higher risk of heart disease later in life. Preeclampsia is a serious pregnancy condition that causes high blood pressure and damages blood vessels. Even after the baby is born, the blood vessels do not fully heal on their own, which can lead to heart problems\u002Fcardiovascular years later.\n\nThis study tests whether a new treatment called exosomes can help repair damaged blood vessels in women who had preeclampsia. Exosomes are tiny particles that come from stem cells and contain healing substances that may help blood vessels work better.\n\n\\---\n\nWhat Will Happen in This Study?\n\nThis study will include 80 women who recently gave birth and had preeclampsia during their pregnancy. Half of the women will receive the exosome treatment through an IV, and half will receive a placebo (a substance with no active treatment).\n\n\\---\n\nWhat Will Participants Need to Do?\n\nParticipants will:\n\n* Have blood tests and other health checks\n* Receive one treatment through an IV\n* Return for follow-up visits at 1 week after treatment\n* Have tests to check how well their blood vessels are working\n\nWho Can Join This Study?\n\nWomen who:\n\n* Recently gave birth (within 1-2 weeks)\n* Had preeclampsia during their last pregnancy\n* Are healthy enough to participate\n* Can give permission to join the study\n\nWhat Are the Possible Benefits and Risks?\n\nThe treatment may help repair blood vessel damage and reduce the risk of future heart disease. The exosome treatment appears to be safe based on other studies, but like any medical treatment, there may be side effects.\n\n\\---\n\nHow Long Will the Study Last?\n\nThe main treatment happens during one visit, with follow-up visits for 1 week to check on participants' health and see if the treatment is working.\n\nThis research may lead to new ways to protect women's heart health after pregnancy complications.",[158,159,160,161,28],"Preeclampsia","Postpartum","Endothelial Injury","Exosome Multiomics",[158,159,163,164,28],"Stem Cell","Exosome","2025-09-12",{"date":167,"type":37},"2025-09-19",{"date":169,"type":37},"2024-07-01",{"date":171,"type":21},"2026-09-01",{"name":173,"class":44},"Universitas Padjadjaran"]